- Home
- WMB vs SNY Comparison
WMB vs SNY Comparison
Compare WMB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WMB | SNY |
|---|---|---|
| Founded | 1908 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0B | 95.7B |
| IPO Year | 2002 | 2001 |
Fundamental Metrics
Financial Performance| Metric | WMB | SNY |
|---|---|---|
| Price | $71.06 | $39.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 10 |
| Target Price | ★ $85.61 | $53.72 |
| AVG Volume (30 Days) | ★ 6.1M | 2.5M |
| Earning Date | 11-02-2026 | 10-30-2026 |
| Dividend Yield | 2.98% | ★ 4.42% |
| EPS Growth | ★ 17.58 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $11,950,000,000.00 | N/A |
| Revenue This Year | $3.37 | $2.00 |
| Revenue Next Year | $13.29 | $6.29 |
| P/E Ratio | $50.16 | ★ $6.14 |
| Revenue Growth | ★ 13.78 | N/A |
| 52 Week Low | $56.19 | $40.40 |
| 52 Week High | $80.08 | $52.68 |
Technical Indicators
Market Signals| Indicator | WMB | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 25.79 |
| Support Level | $69.55 | N/A |
| Resistance Level | $76.25 | $45.22 |
| Average True Range (ATR) | 1.55 | 0.53 |
| MACD | -0.16 | -0.23 |
| Stochastic Oscillator | 63.28 | 2.47 |
Price Performance
Historical ComparisonAbout WMB Williams Companies Inc. (The)
Williams operates the Transco pipeline, which connects the Gulf Coast to the Northeast United States. It has additional natural gas transmission pipelines connecting the Rockies to the Pacific Northwest and midcontinent. At the field level, it operates substantial gathering and processing assets in Appalachia and other basins. The company has also struck several power supply agreements.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.